Curative radiotherapy of localized prostate cancer. Treatment methods and results;Kurative radiotherapie des lokalisierten prostatakarzinoms: Behandlungsverfahren und ergebnisse

Urologe - Ausgabe A

Volumn 42, Issue 9, 2003, Pages 1212-1220

  Schwarz, R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Curative radiotherapy; Localized prostate cancer; Modern treatment methods; Results

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; BLADDER; BLOOD; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; HUMAN; INCIDENCE; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCTITIS; PROGNOSIS; PROSTATE CANCER; PROSTATE TUMOR; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIATION HAZARD; RADIATION PROTECTION; RECTUM; REVIEW; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING; URINE RETENTION;

BRACHYTHERAPY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; HUMANS; MALE; PROCTITIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIATION PROTECTION; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RECTUM; TREATMENT OUTCOME; URINARY BLADDER;

EID: 0141616485     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-003-0428-y     Document Type: Review

References (84)

1. American Society for Therapeutic Radiology and Oncology Consensus Panel (1997) Consensus statement: Guidelines for PSA following radiation therapy. Int J Rad Oncol Biol Phys 37: 1035-1041
2. Andreopoulos D, Piatkowiak M, Krenkel B et al. (1999) Die kombinierte Behandlung des lokal begrenzten Prostatakarzinoms mit HDR-Iridium-192-Nachlade-Brachytherapie und perkutaner Bestrahlung. Strahlenther Onkol 175: 387-391
3. Ash D, Flynn A, Battermann J et al. (2000) ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57: 315-321
4. Bolla M, Gonzalez D, Padraig W et al. (1997) Improved survival in patients with clinically advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337: 295-300
5. Bolla M, Collette L, Blank L et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III trial. Lancet 360: 103-106
6. Bolla M, Collette L, Gonzalez D et al. (1999) Long-term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy. A phase III EORTC study. Eur J Cancer 35 [Suppl 4]: 82
7. Borghede G, Hedelin H, Holmang S et al. (1997) Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 44: 237-244
8. Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43: 1095-1101
9. Brenner DJ, Hall EJ (2000) Low α/β values for prostate cancer appear to be independent of modelling details. Int J Radiat Oncol Biol Phys 47: 538-539
10. Bocci J, Morris WI, Keyes M et al. (2002) Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53: 91-98
11. Cavanagh W, Blasko JC, Grimm PD et al. (2000) Transient elevation of serum prostate specific antigen following I-125/Pd103 brachytherapy for localized prostate cancer. Semin Urol Oncol 18: 160-165
12. Cox JD, Gallagher MJ, Hammond EH et al. (1999) Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J Clin Oncol 17: 1155
13. Critz FA, Tarlton RS, Holladay DA (1995) Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer: I-125 implant followed by external-beam radiation. Cancer 75: 2383-2391
14. Critz FA, Levinson AK, Williams WH et al. (1997) The PSA nadir that indicates potential cur after radiotherapy for prostate cancer. Urology 49: 322-326
15. Crook J, Mclean M, Catton C et al. (2002) Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52: 453-460
16. D'Amico AV, Whittington R, Malkowicz SB et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280: 969-974
17. Davis JW, Kuban DA, Lynch DF et al. (2001) Quality of life after treatment for localized prostate cancer: differences based on treatment modality. J Urol 166: 947-952
18. Dattoli MJ, Wallner KE, Cash JC et al. (1997) Palladium-103 brachytherapy for clinical T1/T2 prostate carcinomas. Int J Radiat Oncol Biol Phys 39: 220
19. Dearneley DP, Khoo VS, Norman AR et al. (1999) Comparison of radiation side-eefects of conformal and conventional radiotherapy in prostate cancer: a randomized trial. Lancet 353: 267-272
20. Deger S, Boehmer D, Turk I et al. (2002) High dose rate brachytherapy of localized prostate cancer. Eur Urol 41: 420-426
21. Desai I, Stock RG, Stone NN et al. (1998) Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat Oncol Investig 6: 135-141
22. Dinges S, Deger S, Koswig S et al. (1998) High-dose rate interstitial brachytherapy with external beam irradiation for localized prostate cancer-results of a prospective trial. Radiother Oncol 48: 197-202
23. Duchesne GM, Peters LJ (1999) What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose rate brachytherapy. Int J Radiat Oncol Biol Phys 44: 747-748
24. Eulau SM, Van Hollebeke L, Cavanagh W et al. (2000) High-dose rate 192-iridium brachytherapy in localized prostate cancer: Results and toxicity with maximum follow-up of 10 years. Int J Radiat Oncol Biol Phys 48 [Suppl]: 149
25. Forman J, Kumar R, Haas G et al. (1995) Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 13: 8
26. Fowler JF, Chappell R, Ritter MA (2001) Is α/β for prostate really low? Int J Radiat Oncol Biol Phys 50: 1021-1031
27. Galalae RM, Kovacz G, Schultze J et al. (2002) Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 52: 81-90
28. Gelblum DY, Potters L (2000) Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 48: 119-124
29. Grimm PD, Blasko JC, Sylvester JE et al. (2001) 10 year biochemical (prostate specific antigen) control of prostate cancer with I-125 brachytherapy. Int J Radiat Oncol Biol Phys 49: 31-40
30. Hanks GE, Lee WR, Hanlon AL et al. (1996) Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostatic specific antigen = 10 ng/ml. Int J Rad Oncol Biol Phys 36: 861-868
31. Hanks GE, Hanlon AL, Schultheiss TE et al. (1998) Dose escalation with 3D conformal treatment: Five year outcomes, treatment optimization, and future directions. Int J Rad Oncol Biol Phys 41: 501-510
32. Hanks GE, Hanlon AL, Pinover WH et al. (2000) Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Rad Oncol Biol Phys 46: 823-832
33. Hanks GE, Hanlon AL, Epstein B et al. (2002) Dose response in prostate cancer with 8-12 years follow-up. Int J Radiat Oncol Biol Phys 54: 427-435
34. Iannuzzi CM, Stock RG, Stone NN (1999) PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer. Radiat Oncol Investig 7: 30-35
35. Incrocci L, Koper PCM, Hop WCJ et al. (2001) Sidenafil citrate (Viagra) and erectile function following external beam radiotherapy for prostate cancer: a randomized, double blind, placebo-controlled, cross over study. Int J Radiat Oncol Biol Phys 51: 1190-1195
36. Kang SK, Chou RH, Dodge RK (2002) Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Int J Radiat Oncol Biol Phys 53: 99-103
37. Kaye KW, Olson DI, Payne IT (1995) Detailed preliminary analysis of 125Iodine implantation for localized prostate cancer using percutaneous approach. J Urol 153: 1020-1025
38. Kleinberg L, Wallner K, Roy J et al. (1994) Treatment related symptoms during the first year following transperineal I-125 prostate implantation. Int J Radiat Oncol Biol Phys 28: 985-990
39. Koper PCM, Stroom JC, van Putten WLI et al. (1999) Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomised study. Int J Radiat Oncol Biol Phys 43: 727-734
40. Kucway R, Vicini F, Huang R et al. (2002) Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 167: 2443-2447
41. Kupelian PA, Mohan DM, Lyons J et al. (2000) Higher than standard radiation doses (=72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Rad Oncol Biol Phys 46: 567-574
42. Kupelian PA, Elshaik M, Reddy CA et al. (2002) Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single institution experience with radical prostatectomy and external-beam radiotherapy. JCO 20: 3376-3385
43. Laverdiere J, Gomez JL, Cusan L et al. (1997) Benefical effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37: 247-252
44. Lederman GS, Cavanagh W, Albert PS et al. (2001) Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys 49: 1297-1303
45. Lee LN, Stock RG, Stone NN (2002) The role of hormone therapy in the management of intermediate to high risk prostate cancer treated with permanent radioactive seed implantation. Int J radiat Oncol Biol Phys 52: 444-452
46. Magrini SM, Cellai E, Pertici M et al. (1998) Radical radiotherapy of localized prostate cancer. Cancer Radiother 2: 351-358
47. Martin T, Hey-Koch S, Strassmann G et al. (2000) 3D interstitial HDR brachytherapy combined with 3d external beam radiotherapy and androgen deprivation for prostate cancer. Strahlenther Onkol 176: 361-367
48. Martinez AA, Kestin LL, Stromberg JS et al. (2000) Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: The William Beaumont Phase II dose-escalating trial. Int J Radiat Oncol Biol Phys 47: 343-352
49. Martinez AA, Gonzalez JA, Chung AK et al. (2000) A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer 88: 425-432
50. Martinez AA, Pataki I, Edmundson G et al. (2001) Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys 49: 61-69
51. 192Iridium prostate brachytherapy: Feasibility report. Int J Radiat Oncol Biol Phys 41: 525-533
52. Merrick GS, Butler WM, Galbreath RW et al. (2002) Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 52: 893-902
53. Nag S, Beyer D, Friedland J et al. (1999) American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44: 789-799
54. Pilepich MV, Sause WT, Shipley WU et al. (1995) Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomised comparative trial of the Radiation Therapy Oncology Group. Urology 45: 616-623
55. Pilepich MV, Caplan R, Byhardt RW et al. (1997) Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15: 1013-1021
56. Pollack A, Zagars GK (1997) External beam radiotherapy dose response of prostate cancer. Int J Rad Oncol Biol Phys 39: 1011-1018
57. Pollack A, Zagars G, Starkschall G et al. (2002) Prostate cancer radiation dose response: results of the M.D.Anderson phase III randomised trial. Int J Radiat Oncol Biol Phys 53: 1097-1105
58. Potters L, Gao Y, Calugaru E et al. (2001) A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50: 605-614
59. Potters L, Torre T, Fearn PA et al. (2001) Potency in permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50: 1235-1242
60. Ragde H, Abdel-Aziz AE, Snow PB et al. (1998) Ten year-disease free survival after transperineal sonography-guided Iodine-125 brachytherapy with or without 45 Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 83: 989-1001
61. Ragde H, Grado GI, Nadir BS (2001) Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol 54: 739-747
62. Snyder KM, Stock RG, Hong SM et al. (2001) Defining the risk of developing grade 2 proctitis following I-125 prostate brachytherapy using a rectal dose volume histogram analysis. Int J Radiat Oncol Biol Phys 50: 335-341
63. Stock RG, Stone NN, Yeghiayan P (1998) Neoadjuvant androgen suppression and permanent radioactive seed implantation in the treatment of stage T1-T2 prostate cancer. Mol Urol 2: 121-127
64. Stock RG, Stone NN, Tabert A et al. (1998) A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41: 101-108
65. Stock RG, Stone NN, Hong S (2001) Is long term hormonal therapy needed with dose escalation in high risk prostate cancer? Results of treatment with 9 months of hormonal therapy, brachytherapy and 3D conformal external beam irradiation. Int J Radiat Oncol Biol Phys 51: 2127
66. Stone NN, Stock RG (1999) Neoadjuvant hormonal therapy improves the outcomes of patients undergoing radioactive seed implantation for localized prostate cancer. Mol Urol 3: 239-245
67. Stone NN, Stock RG, Unger P et al. (2000) Biopsy results following real-time ultrasound-guided transperineal implants for T1-T2 prostate cancer. J Endourol 14: 379-384
68. Stone NN, Stock RG (2000) Prospective 10 year analysis of urinary symptoms and quality of life in men with large or small prostates treated with prostate brachytherapy. Int J Radiat Oncol Biol Phys 48 [Suppl]: 1006
69. Stone NN, Ratnow ER, Stock RG (2000) Prior transurethral resection does not increase morbidity following real time guided prostate seed implantation. Tech Urol 6: 123-127
70. Stromberg J, Martinez A, Gonzalez J et al. (1995) Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 33: 161-171
71. Terk MD, Stock RG, Stone NN (1998) Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 160: 1379-1382
72. Valicenti R, Lu J, Pilepich M et al. (2000) Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 18: 2740-2746
73. Wallner K, Roy J, Harrison L (1996) Tumor control and morbidity following transperineal iodine implantation for stage T1/T2 prostatatic carcinoma. J Clin Oncol 14: 449-453
74. Wirth MP, Hermann T, Alken P et al. (2002) Empfehlungen zur Durchführung der alleinigen permanenten, interstitiellen Brachytherapie beim lokal begrenzten Prostatakarzinom Strahlenther Onkol 178: 115-119
75. Whittington R, Broderick G, Arger P et al. (1999) The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys 44: 1107-1110
76. Yoshioka Y, Nose T, Yoshioda K et al. (2000) High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys 48: 675-681
77. Wei JT, Dunn RL, Sandler HM et al. (2002) Comprehensive comparison of health related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 20: 557-566
78. Zeitlin SI, Sherman J, Raboy A et al. (1998) High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 160: 91-96
79. Zelefsky MJ, Leibel SA, Kutcher GJ et al. (1995) The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma. Cancer J Sci Amer 1: 142-150
80. Zelefsky MJ, Aschkenasy E, Kelsen S et al. (1997) Tolerance and early outcome results of postprostatectoms three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 39: 327-333
81. Zelefsky M, Harrison A (1997) Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 43 [Suppl]: 38
82. Zelefsky MJ, Leibel SA, Gaudin PB et al. (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Rad Oncol Biol Phys 41: 491-500
83. Zelefsky MJ, Fuks Z, Happersett L et al. (2000) Clinical experience with intensity modulated radiation Therapy (IMRT) in prostate cancer. Radiother Oncol 55: 241-249
84. Zelefsky MJ, Fuks Z, Hunt M et al. (2002) High dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical in 772 patients. Int J Radiat Oncol boil Phys 53: 1111-1116